Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLV9 | ISIN: FR0013233012 | Ticker-Symbol: 6IV
Tradegate
27.06.25 | 19:12
2,620 Euro
-1,32 % -0,035
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INVENTIVA SA Chart 1 Jahr
5-Tage-Chart
INVENTIVA SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,5952,65521:20
2,6052,65521:06

Aktuelle News zur INVENTIVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.06.INVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors444Daix (France), New York City (New York, United States), June 10, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused...
► Artikel lesen
27.05.INVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference304Daix (France), New York City (New York, United States), May 27, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on...
► Artikel lesen
INVENTIVA Aktie jetzt für 0€ handeln
23.05.Inventiva S.A. reports Q1 results1
23.05.INVENTIVA: Inventiva reports 2025 First Quarter Financial Information349Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical...
► Artikel lesen
23.05.INVENTIVA: Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025169Daix (France), New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development...
► Artikel lesen
22.05.Inventiva S.A. - 6-K, Report of foreign issuer2
22.05.Inventiva sets share repurchase program terms post-meeting5
22.05.INVENTIVA: Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux252Daix, May 22, 2025 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l'Autorité des marchés financiers), the purpose of this description is to present the objectives...
► Artikel lesen
05.05.Inventiva secures €116 million second tranche of structured financing of up to €348 million2
05.05.INVENTIVA: Inventiva secures the €116 million second tranche of its structured financing of up to €348 million342Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United...
► Artikel lesen
02.05.Inventiva S.A. - 6-K, Report of foreign issuer2
30.04.INVENTIVA: Statement of total voting rights and shares forming the company's share capital as of April 11, 2025246Article R. 22-10-23 of the French Commercial Code Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com DateNumber of shares outstandingTotal voting rights...
► Artikel lesen
30.04.INVENTIVA: Combined General Meeting of May 22, 2025 - Availability of the preparatory documents273Daix (France), New York City (New York, United States), April 30, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small...
► Artikel lesen
24.04.INVENTIVA: Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor320? Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ? The biomarker signatures developed for fibrosis improvement...
► Artikel lesen
24.04.Inventiva S.A. - 6-K, Report of foreign issuer3
15.04.INVENTIVA: Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F662Daix (France), New York City (New York, United States), April 15, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused...
► Artikel lesen
15.04.Inventiva S.A. - 20-F, Annual and transition report of foreign private issuers2
11.04.Inventiva S.A. - 6-K, Report of foreign issuer3
04.04.Guggenheim cuts Inventiva stock target to $9, maintains Buy rating1
02.04.Inventiva stock rises following NATiV3 trial enrollment completion3
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1